Medicines
Medicines approved for MS and related diseases, and those in development, each linked to its trials.
176 medicines
| Medicine | Approach | Furthest phase | Trials | Latest trial started | Status of the latest trial |
|---|---|---|---|---|---|
| remibrutinib | BTK inhibition (B cells and microglia) | Phase 3 | 6 | Mar 2027 | Not yet recruiting |
| frexalimab | T-cell co-stimulation / cytokine targeting | Phase 3 | 5 | Feb 2027 | Not yet recruiting |
| arbaclofen | Spasticity | Phase 3 | 5 | Jan 2027 | Not yet recruiting |
| clemastine | Remyelination / oligodendrocyte repair | Phase 3 | 5 | Sept 2026 | Not yet recruiting |
| cyclophosphamide anhydrous | Broad immunosuppression / cytotoxics | Phase 3 | 27 | Sept 2026 | Not yet recruiting |
| tocilizumab | IL-6 pathway | Phase 3 | 4 | Sept 2026 | Not yet recruiting |
| efgartigimod alfa | FcRn / IgG reduction, IVIG, plasma exchange | Phase 3 | 3 | Jun 2026 | Not yet recruiting |
| orelabrutinib | BTK inhibition (B cells and microglia) | Phase 3 | 5 | Mar 2026 | Recruiting |
| omega-3 fatty acids | Vitamin D and nutritional supplements | Phase 3 | 5 | Jan 2026 | Enrolling by invitation |
| cannabidiol | Spasticity | Phase 3 | 6 | Dec 2025 | Recruiting |
| dronabinol | Axonal protection / ion channels / excitotoxicity, Spasticity | Phase 3 | 14 | Dec 2025 | Recruiting |
| naltrexone | Pain, mood, cognition and other symptoms | Phase 3 | 3 | Oct 2025 | Enrolling by invitation |
| fenebrutinib | BTK inhibition (B cells and microglia) | Phase 3 | 8 | Oct 2025 | Recruiting |
| masitinib | Microglia / innate immunity in the CNS | Phase 3 | 7 | Feb 2024 | Stopped early |
| divozilimab | B-cell depletion (anti-CD20) | Phase 3 | 2 | Dec 2022 | Running, not recruiting |
| amantadine | Fatigue / wakefulness | Phase 3 | 6 | Nov 2022 | Status unknown |
| daratumumab | Other B-cell / plasma-cell targeting | Phase 3 | 1 | Nov 2022 | Running, not recruiting |
| vibegron | Bladder | Phase 3 | 1 | Oct 2022 | Recruiting |
| vidofludimus | DHODH inhibition (pyrimidine synthesis) | Phase 3 | 7 | May 2022 | Moved to EU CTIS registry |
| rozanolixizumab | FcRn / IgG reduction, IVIG, plasma exchange | Phase 3 | 1 | Feb 2022 | Running, not recruiting |
| rimabotulinumtoxinb | Spasticity | Phase 3 | 1 | Nov 2021 | Stopped early |
| methylprednisolone acetate | Corticosteroids (relapse treatment) | Phase 3 | 1 | Jun 2021 | Status unknown |
| evobrutinib | BTK inhibition (B cells and microglia) | Phase 3 | 5 | Jul 2020 | Stopped early |
| minocycline | Microglia / innate immunity in the CNS | Phase 3 | 4 | Jan 2020 | Stopped early |
| human immunoglobulin g | FcRn / IgG reduction, IVIG, plasma exchange | Phase 3 | 5 | Nov 2019 | Withdrawn |
| botulinum toxin type a | Spasticity | Phase 3 | 9 | Sept 2018 | Ongoing |
| thioctic acid | Mitochondrial / oxidative stress | Phase 3 | 5 | Aug 2018 | Completed |
| methylphenidate | Fatigue / wakefulness | Phase 3 | 5 | Oct 2017 | Completed |
| interferon beta | Interferon beta | Phase 3 | 6 | Jul 2017 | Status unknown |
| biotin | Mitochondrial / oxidative stress | Phase 3 | 4 | Dec 2016 | Stopped early |
| baclofen | Spasticity | Phase 3 | 3 | Apr 2016 | Completed |
| laquinimod | T-cell co-stimulation / cytokine targeting | Phase 3 | 10 | Jan 2015 | Completed |
| epoetin alfa | Axonal protection / ion channels / excitotoxicity | Phase 3 | 2 | Nov 2014 | Completed |
| dextromethorphan | Pain, mood, cognition and other symptoms | Phase 3 | 3 | Nov 2011 | Completed |
| arbaclofen placarbil | Spasticity | Phase 3 | 1 | May 2011 | Completed |
| calcium | Vitamin D and nutritional supplements | Phase 3 | 1 | Oct 2010 | Stopped early |
| pregabalin | Axonal protection / ion channels / excitotoxicity, Pain, mood, cognition and other symptoms | Phase 3 | 2 | Sept 2010 | Completed |
| armodafinil | Fatigue / wakefulness | Phase 3 | 1 | Sept 2009 | Completed |
| escitalopram | Pain, mood, cognition and other symptoms | Phase 3 | 1 | Jul 2009 | Completed |
| rivastigmine | Pain, mood, cognition and other symptoms | Phase 3 | 1 | Mar 2009 | Completed |
| nomegestrol acetate | Sex hormones / hormonal | Phase 3 | 2 | Oct 2008 | Ongoing |
| duloxetine | Pain, mood, cognition and other symptoms | Phase 3 | 3 | Oct 2008 | Completed |
| dirucotide | Cell therapies and tolerisation | Phase 3 | 6 | Jun 2007 | Stopped early |
| tizanidine | Spasticity | Phase 3 | 2 | Dec 2006 | Completed |
| amifampridine | Walking (potassium-channel blockade) | Phase 3 | 2 | Jun 2006 | Completed |
| pravastatin | Lipid / vascular (statins etc.) | Phase 3 | 1 | Dec 2004 | Completed |
| onabotulinumtoxina | Spasticity, Bladder | Phase 4 | 10 | Apr 2027 | Ongoing (inferred) |
| nabiximols | Spasticity | Phase 4 | 27 | Dec 2026 | Withdrawn |
| rituximab | B-cell depletion (anti-CD20) | Phase 4 | 40 | Sept 2026 | Recruiting |
| crisugabalin | Pain, mood, cognition and other symptoms | Phase 4 | 1 | Jun 2026 | Not yet recruiting |
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error